Losing weight during adolescence can lower the muscle and bone ceiling for life
In short
GLP-1 receptor agonists such as semaglutide and liraglutide produce significant weight loss and cardiometabolic improvement in pediatric obesity, and by easing pain, mechanical load and psychosocial burden they open a window in which physical activity becomes possible. The concern is timing: adolescence is when muscle and bone mass accrue fastest, and weight loss during it may attenuate that accrual, lowering peak musculoskeletal capacity and raising future frailty risk. The authors' prescription is not to withhold the drug but to build resistance training, weight-bearing activity and adequate protein into the same treatment plan.
The open question about GLP-1 drugs in adolescents is not whether they work. They do — weight falls, cardiometabolic markers improve, and reductions in pain, mechanical load and psychosocial burden leave a teenager able to start moving. The open question is that this weight loss lands during the one stretch of life when muscle and bone accrue fastest.
Why does adolescence specifically matter?
Muscle mass and bone mass are not accumulated evenly across a lifetime. Most of both is laid down in adolescence, and the value reached then becomes the ceiling drawn on for decades afterwards. The concern raised here is straightforward: if weight loss blunts that accrual, peak musculoskeletal capacity itself comes in lower, and the shortfall is subtracted from a lifetime reserve rather than made up later. The authors link this to increased frailty risk in the future.
Is this a trial result?
No. This is a perspective piece, and the authors open by stating that longitudinal pediatric data are limited. It does not quantify how much peak bone or muscle mass adolescent weight loss actually costs; it argues how clinicians should prescribe while that evidence is still missing. Erasing that distinction puts words in the paper's mouth.
What do the authors actually recommend?
Not to leave the drug standing alone, but to place it inside a multimodal framework: resistance training, weight-bearing activity that loads bone, and optimized nutrition with adequate protein intake to preserve lean mass. Exercise is not only damage control during weight loss — the authors argue it may synergize with GLP-1-mediated metabolic improvements to enhance functional outcomes. One sentence carries the paper: pharmacotherapy is not a substitute for lifestyle intervention.
This is a perspective piece rather than a clinical guideline, and longitudinal pediatric data remain limited. Prescribing, dosing and discontinuation are decisions for the treating clinician, and nothing here replaces that. GLP-1 use and training performance in adults is covered in GLP-1 drugs and training performance, and the loading needed by bone in the training dose that raises bone density.
Should a teenager be lifting barbells?
Resistance training and weight-bearing activity is precisely what this paper asks for, so the answer is yes. The folk rule that strength training should wait until growth is finished sits directly against this position. Bone raises density when it is loaded, and muscle is retained during weight loss only when it is stimulated. Given supervision and sensible loading, adolescence is not the phase to postpone lifting — it is the phase with the highest return. Where to begin is covered in how to start barbell training.
What should be tracked during weight loss?
Body weight alone is the wrong metric. The one live signal that muscle is being protected is whether absolute Big 3 loads hold. If squat, bench and deadlift fall alongside body weight, the rate of loss is eating muscle; if weight falls and the loads hold, it is going well. One trap deserves naming: a bodyweight-adjusted strength score rises on its own as body weight drops. Watching the score alone hides muscle loss, so in a cut the absolute loads and the score have to be logged side by side.
Frequently asked questions
Do GLP-1 drugs stunt muscle and bone growth in adolescents?
It has been raised as a concern rather than demonstrated with numbers. Adolescence is when muscle and bone mass accrue fastest, and this paper argues weight loss during that period may attenuate accrual and lower peak musculoskeletal capacity. Longitudinal pediatric data are still limited.
What kind of study is this?
A perspective piece, not a trial. It synthesises existing evidence to argue for integrating tailored exercise prescription with GLP-1 therapy, and it explicitly notes that long-term pediatric data are lacking.
How do you protect muscle while on the medication?
The authors name three things: resistance training, weight-bearing activity that loads bone, and adequate protein intake to preserve lean mass. The point is to treat these as components of the same treatment plan rather than optional extras alongside the drug.
Can GLP-1 drugs help someone exercise more?
Indirectly, yes. As weight falls, pain, mechanical joint load and psychosocial burden all decrease, lowering the barriers that made activity hard to start. The paper treats this as a window in which sustainable habits can be established.
How do you tell whether a cut is costing muscle?
By absolute Big 3 loads, not the scale. If squat, bench press and deadlift hold while body weight falls, lean mass is probably being preserved. A bodyweight-adjusted score climbs automatically as weight drops, so it cannot be used on its own to make that call.
Source: PubMed